Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal.
It’s not an easy time to be an American multinational company that sells to or buys from China. As the governments of the United States and China butt heads, they’re pressuring companies to ...
As China sits on the precipice of deflation, Wall Street economists are calling for more fiscal stimulus in the country. But Beijing may still not act boldly enough. While much of the West has ...
SINGAPORE—While China asserts a more muscular influence on global affairs, Western experts face growing constraints in their efforts to study the emerging superpower. Scholars researching ...
As corporations like Microsoft, Dell, Stanley Black & Decker, Blizzard Entertainment, and Airbnb pull back on China, dozens of others are shifting their global footprints, sighting everything from ...
China will raise the retirement age for the first time since 1978, a move that could stem a decline in the labor force but risk angering workers already wrestling with a slowing economy.
In response to China's enhanced air combat capabilities along the frontier, the Indian Air Force is upgrading its airbases and expediting the delivery of Tejas fighters. Despite technological lags ...
WHO’s assessment for prequalification is based on data submitted by Bavarian Nordic and review by the European Medicines ...
Guangzhou is setting the tone for policy deregulation across the country, says Yan Yuejin of E-house China Research and Development Institute. New World Development and another listed unit were ...
China has strongly advised its carmakers to make sure advanced electric vehicle technology stays in the country, people familiar with the matter said, even as they build factories around the world ...
Pork is served in Bavarian inns mainly in two variants. One is "Schweinebraten" (roast pork), which comes from the back or shoulder of the pig and is braised in the oven. In Bavaria, it is usually ...
If the demand is there and the other conditions are in place, we have the opportunity to increase by another 50 million doses," Bavarian's head of investor relations Rolf Sass Sorensen said.